Novavax, Inc. (NVAX) — closed signal from March 9, 2026
Partial Published before the outcome was known, scored automatically when the window closed on June 7, 2026.
Predicted vs. what happened
What happened
Reached 44% of the predicted growth at its peak, without hitting the target.
The thesis — published March 9, 2026
Recent news turned Novavax from a hopeful idea into a company that is actually making money now. Unexpected profit, growing license payments, and a contract with Pfizer give clearer cash flow. Trading interest is still healthy, but changes at the FDA can quickly change sentiment, so treat this as a short-term, sized trade for accounts that can handle risk.
Primary drivers
- Unexpected profit and licensing make near-term cash clearer
- Royalties from Pfizer and Sanofi improve predictable cash flow
- Trading interest stayed strong after the recent rise in price
- Positive vaccine updates could lift the stock even if market is flat
How it played out
NVAX: target was not reached
Lyra published NVAX on 2026-03-09 at $10.51, with expected growth of 24% and a target of $13.03. The thesis pointed to unexpected profit and licensing, royalties from Pfizer and Sanofi, healthy trading interest after the recent rise, and possible vaccine updates as short-term drivers.
Inside the 2026-03-09 to 2026-06-07 window, NVAX rose to a peak of $11.61 on 2026-05-27, a 10.5% gain. It stayed below the $13.03 target and never reached it. The stock ended at $9.49. The thesis partially played out, but missed the target.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.